Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 17-26

  Asakura, Keiichi ^a,b,c,d,e   Hayashi, Seiji ^a,b,e   Ojima, Atsuko ^b,f   Taniguchi, Tomohiko ^b,c,d,f   Miyamoto, Norimasa ^b,c,d,f   Nakamori, Chiaki ^d,g   Nagasawa, Chiho ^d,g   Kitamura, Tetsuo ^d,h   Osada, Tomoharu ^a,b,h   Honda, Yayoi ^d,i   Kasai, Chieko ^a,b,j   Ando, Hiroyuki ^a,b,d,k   Kanda, Yasunari ^a,b,l   Sekino, Yuko ^a,b,l   Sawada, Kohei ^a,b,f  

^a Japanese Safety Pharmacology Society (JSPS)   (Japan)

^b Japan iPS Cardiac Safety Assessment (JiCSA)   (Japan)

^c Drug Evaluation Committee   (Japan)

^d Consortium for Safety Assessment using Human iPS Cells ^*  (Japan)

^e NIPPON SHINYAKU CO LTD   (Japan)

^f EISAI CO LTD   (Japan)

^g TAISHO PHARMACEUTICAL CO LTD   (Japan)

^h LSI MEDIENCE CORPORATION   (Japan)

ⁱ DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^j ASTELLAS PHARMA INC   (Japan)

^k ONO PHARMACEUTICAL CO   (Japan)

^l NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

more..

Author keywords

Action potential; Field potential; High pass filter; Human induced pluripotent stem cell derived cardiomyocytes; Membrane potential dye; Multi electrode array

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ACETYLSALICYLIC ACID; MOXIFLOXACIN; TERFENADINE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACQUISITION METHOD; ACTION POTENTIAL AMPLITUDE; ANALYTIC METHOD; APD50; APD90; ARTICLE; CELL DENSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTRIC POTENTIAL; ELECTRICAL POTENTIAL PARAMETERS; HEART BEAT; HEART MUSCLE CELL; HIGH PASS FILTER FREQUENCY; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL DERIVED CARDIOMYOCYTE; MICROARRAY ANALYSIS; MULTI ELECTRODE ARRAY; QT PROLONGATION; REPOLARIZATION; ACTION POTENTIAL; ARRHYTHMIAS, CARDIAC; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; INDUCED PLURIPOTENT STEM CELL; LONG QT SYNDROME;

ACTION POTENTIALS; ARRHYTHMIAS, CARDIAC; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LONG QT SYNDROME; MYOCYTES, CARDIAC; PIPERIDINES; PYRIDINES; TERFENADINE;

EID: 84942374527     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.04.002     Document Type: Article

References (31)

1. Cavero I. 13th Annual Meeting of the Safety Pharmacology Society: Focus on novel technologies and safety pharmacology frontiers. Expert Opinion on Drug Safety 2014, 13(9):1271-1281.
2. Cavero I., Holzgrefe H. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative. Expert Opinion on Drug Safety 2014, 13(6):745-758.
3. Fejtl M., Stett A., Nisch W., Boven K.H., Möller A. On micro-electrode array revival: Its development, sophistication of recording, and stimulation. Advances in network electrophysiology 2006, 24-37. Springer, US.
4. Gibson J.K., Yue Y., Bronson J., Palmer C., Numann R. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. Journal of Pharmacological and Toxicological Methods 2014, 70(3):255-267.
5. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacology & Therapeutics 2011, 129(2):109-119.
6. Halbach M.D., Egert U., Hescheler J., Banach K. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cellular Physiology and Biochemistry 2003, 13(5):271-284.
7. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicological Sciences 2013, 134(2):412-426.
8. Hayakawa T., Kunihiro T., Ando T., Kobayashi S., Matsui E., Yada H., et al. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. Journal of Molecular and Cellular Cardiology 2014, 77:178-191.
9. Hayashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. Journal of Pharmacological Sciences 2005, 99(5):423-437.
10. Kaneko T., Nomura F., Hamada T., Abe Y., Takamori H., Sakakura T., et al. On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Scientific Reports 2014, 4(Article number: 4670).
11. Lu H.R., Vlaminckx E., Hermans A.N., Rohrbacher J., Van Ammel K., Towart R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. British Journal of Pharmacology 2008, 154(7):1427-1438.
12. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. American Journal of Physiology. Heart and Circulatory Physiology 2011, 301(5):H2006-H2017.
13. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 2004, 43(3):369-379.
14. Meiry G., Reisner Y., Feld Y., Goldberg S., Rosen M., Ziv N., et al. Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes. Journal of Cardiovascular Electrophysiology 2001, 12(11):1269-1277.
15. Meyer T., Boven K.H., Günther E., Fejtl M. Micro-electrode arrays in cardiac safety pharmacology. Drug Safety 2004, 27(11):763-772.
16. Nakamura Y., Matsuo J., Miyamoto N., Ojima A., Ando K., Kanda Y., et al. Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: Multi-site validation study. Journal of Pharmacological Sciences 2014, 124(4):494-501.
17. Nozaki Y., Honda Y., Tsujimoto S., Watanabe H., Kunimatsu T., Funabashi H. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicology and Applied Pharmacology 2014, 278(1):72-77.
18. Obiol-Pardo C., Gomis-Tena J., Sanz F., Saiz J., Pastor M.A. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. Journal of Chemical Information and Modeling 2011, 51:483-492.
19. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2010, 61(3):277-286.
20. Peters M.F., Lamore S.D., Guo L., Scott C.W., Kolaja K.L. Human stem cell-derived cardiomyocytes in cellular impedance assays: Bringing cardiotoxicity screening to the front line. Cardiovascular Toxicology 2015, 15(2):127-139.
21. Pine J. A history of MEA development. Advances in network electrophysiology 2006, 3-23. Springer, US. M. Taketani, M. Baudru (Eds.).
22. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58(1):32-45.
23. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal 2014, 167(3):292-300.
24. Spira M.E., Hai A. Multi-electrode array technologies for neuroscience and cardiology. Nature Nanotechnology 2013, 8(2):83-94.
25. Tanaka T., Tohyama S., Murata M., Nomura F., Kaneko T., Chen H., et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochemical and Biophysical Research Communications 2009, 385(4):497-502.
26. Thomas C.A., Springer P.A., Loeb G.E., Berwald-Netter Y., Okun L.M. A miniature microelectrode array to monitor the bioelectric activity of cultured cells. Experimental Cell Research 1972, 74(1):61-66.
27. Uesugi M., Ojima A., Taniguchi T., Miyamoto N., Sawada K. Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2014, 69(2):177-188.
28. Egert Ulrich, Meyer Thomas Heart on a Chip - Extracellular Multielectrode Recordings from Cardiac Myocytes in Vitro. Practical Methods in Cardiovascular Research, pp 2005, 432-453.
29. Egert Ulrich, Banach Kathrin, Meyer Thomas Analysis of Cardiac Myocyte Activity Dynamics with Micro-Electrode Arrays. Advances in Network Electrophysiology, pp 2006, 274-290.
30. Yamazaki K., Hihara T., Kato H., Fukushima T., Fukushima K., Taniguchi T., et al. Beat-to-beat variability in field potential duration in human embryonic stem cell-derived cardiomyocyte clusters for assessment of arrhythmogenic risk, and a case study of its application. Pharmacology and Pharmacy 2014, 5:117-128.
31. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., et al. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicology in Vitro 2012, 26(2):335-342.